X4 Pharmaceuticals
Susan Dubuc currently serves as the VP of Pharmacovigilance & Risk Management at X4 Pharmaceuticals, a position held since October 2022. Prior to this role, Susan held the title of Sr. Director of Pharmacovigilance & Risk Management. With experience spanning from April 2007 to the present, Susan has worked as a Pharmacovigilance Professional across multiple pharmaceutical companies, demonstrating extensive expertise in the field.
This person is not in any offices
X4 Pharmaceuticals
3 followers
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance.